Skip to content
lifestyle.entreprenerd.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Design Therapeutics, Inc.
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
September 2, 2026
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
August 3, 2026
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
June 30, 2026
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
May 28, 2026
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
May 18, 2026
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
May 17, 2026
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
April 28, 2026